{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:33:26Z","timestamp":1791758006418,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":239,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Reports"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.toxrep.2021.08.005","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T11:38:59Z","timestamp":1630323539000},"page":"1592-1598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Correlation of elevated lamotrigine and levetiracetam serum\/plasma levels with toxicity: A long-term retrospective review at an academic medical center"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8602-5502","authenticated-orcid":false,"given":"Kelly E.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra L.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-8402","authenticated-orcid":false,"given":"Matthew D.","family":"Krasowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.toxrep.2021.08.005_bib0005","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.toxrep.2021.08.005_bib0010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cca.2014.06.002","article-title":"Advances in anti-epileptic drug testing","volume":"436","author":"Krasowski","year":"2014","journal-title":"Clin. Chim. Acta"},{"issue":"12","key":"10.1016\/j.toxrep.2021.08.005_bib0015","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-013-0088-z","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.toxrep.2021.08.005_bib0020","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.toxrep.2021.08.005_bib0025","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.toxrep.2021.08.005_bib0030","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.addr.2011.11.006","article-title":"Chemical properties of antiepileptic drugs (AEDs)","volume":"64","author":"Bialer","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.toxrep.2021.08.005_bib0035","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/00003495-199550040-00008","article-title":"Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy","volume":"50","author":"Fitton","year":"1995","journal-title":"Drugs"},{"issue":"19","key":"10.1016\/j.toxrep.2021.08.005_bib0040","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2165\/00003495-200363190-00009","article-title":"Lamotrigine: a review of its use in bipolar disorder","volume":"63","author":"Goldsmith","year":"2003","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.toxrep.2021.08.005_bib0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","article-title":"Lamotrigine clinical pharmacokinetics","volume":"25","author":"Rambeck","year":"1993","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.toxrep.2021.08.005_bib0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/15563650.2017.1370096","article-title":"Acute lamotrigine overdose: a systematic review of published adult and pediatric cases","volume":"56","author":"Alyahya","year":"2018","journal-title":"Clin. Toxicol. (Phila)"},{"issue":"1","key":"10.1016\/j.toxrep.2021.08.005_bib0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s13181-012-0210-x","article-title":"Case files of the university of California san francisco medical toxicology fellowship: lamotrigine toxicity","volume":"8","author":"Fleurat","year":"2012","journal-title":"J. Med. Toxicol."},{"issue":"5","key":"10.1016\/j.toxrep.2021.08.005_bib0060","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/WNF.0000000000000172","article-title":"Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach","volume":"39","author":"Greenberg","year":"2016","journal-title":"Clin. Neuropharmacol."},{"issue":"11","key":"10.1016\/j.toxrep.2021.08.005_bib0065","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1345\/aph.1E192","article-title":"Evaluation of lamotrigine toxicity reported to poison centers","volume":"38","author":"Lofton","year":"2004","journal-title":"Ann. Pharmacother."},{"issue":"7","key":"10.1016\/j.toxrep.2021.08.005_bib0070","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/15563650.2013.818685","article-title":"A case series of patients with lamotrigine toxicity at one center from 2003 to 2012","volume":"51","author":"Moore","year":"2013","journal-title":"Clin. Toxicol. (Phila)"},{"issue":"1","key":"10.1016\/j.toxrep.2021.08.005_bib0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1520\/JFS14634J","article-title":"Postmortem investigation of lamotrigine concentrations","volume":"45","author":"Pricone","year":"2000","journal-title":"J. Forensic Sci."},{"issue":"8","key":"10.1016\/j.toxrep.2021.08.005_bib0080","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1046\/j.1528-1157.2001.0420081082.x","article-title":"Stupor from lamotrigine toxicity","volume":"42","author":"Sbei","year":"2001","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.toxrep.2021.08.005_bib0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13181-014-0384-5","article-title":"Clinical outcomes in newer anticonvulsant overdose: a poison center observational study","volume":"10","author":"Wills","year":"2014","journal-title":"J. Med. Toxicol."},{"issue":"6","key":"10.1016\/j.toxrep.2021.08.005_bib0090","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2125.1998.00835.x","article-title":"Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service","volume":"46","author":"Morris","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"Suppl 7","key":"10.1016\/j.toxrep.2021.08.005_bib0095","first-page":"240","article-title":"Effective levetiracetam doses and serum concentrations: age effects","volume":"43","author":"Leppik","year":"2002","journal-title":"Epilepsia"},{"issue":"26","key":"10.1016\/j.toxrep.2021.08.005_bib0100","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.toxrep.2021.08.005_bib0105","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s40263-015-0289-0","article-title":"Intravenous and intramuscular formulations of antiseizure drugs in the treatment of epilepsy","volume":"29","author":"Patel","year":"2015","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.toxrep.2021.08.005_bib0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.yebeh.2007.05.006","article-title":"Accidental overdosage of levetiracetam in two children caused no side effects","volume":"11","author":"Awaad","year":"2007","journal-title":"Epilepsy Behav."},{"issue":"4","key":"10.1016\/j.toxrep.2021.08.005_bib0115","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/pds.2113","article-title":"Safety of non-therapeutic levetiracetam ingestions--a poison center based study","volume":"20","author":"Bodmer","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"5","key":"10.1016\/j.toxrep.2021.08.005_bib0120","article-title":"Anti-epileptic drug toxicity in children","volume":"5","author":"Choonara","year":"2018","journal-title":"Children (Basel)"},{"issue":"42 Suppl 4","key":"10.1016\/j.toxrep.2021.08.005_bib0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1528-1167.2001.00008.x","article-title":"Safety profile of levetiracetam","author":"Harden","year":"2001","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.toxrep.2021.08.005_bib0130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2710.2012.01361.x","article-title":"Overdose with levetiracetam: a case report and review of the literature","volume":"38","author":"Larkin","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.toxrep.2021.08.005_bib0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12028-009-9185-0","article-title":"Safety and efficacy of levetiracetam for critically ill patients with seizures","volume":"11","author":"Nau","year":"2009","journal-title":"Neurocrit. Care"},{"issue":"2","key":"10.1016\/j.toxrep.2021.08.005_bib0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5582\/ddt.2016.01082","article-title":"Levetiracetam and topiramate poisoning: two overdoses on those drugs with no lasting effects","volume":"11","author":"Sarfaraz","year":"2017","journal-title":"Drug Discov. Ther."},{"issue":"5","key":"10.1016\/j.toxrep.2021.08.005_bib0145","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/FTD.0000000000000202","article-title":"Comparison of the QMS analyzer with HPLC-UV for the quantification of lamotrigine concentrations in human plasma samples","volume":"37","author":"Baldelli","year":"2015","journal-title":"Ther. Drug Monit."},{"issue":"3\u20134","key":"10.1016\/j.toxrep.2021.08.005_bib0150","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cca.2011.11.018","article-title":"Performance characteristics and patient comparison of the ARK Diagnostics levetiracetam immunoassay with an ultra-high performance liquid chromatography with tandem mass spectrometry detection method","volume":"413","author":"Juenke","year":"2012","journal-title":"Clin. Chim. Acta"},{"issue":"19\u201320","key":"10.1016\/j.toxrep.2021.08.005_bib0155","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.cca.2011.06.009","article-title":"A comparison of two FDA approved lamotrigine immunoassays with ultra-high performance liquid chromatography tandem mass spectrometry","volume":"412","author":"Juenke","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.toxrep.2021.08.005_bib0160","doi-asserted-by":"crossref","DOI":"10.5858\/arpa.2020-0562-CP","article-title":"Therapeutic drug monitoring of second- and third-generation antiepileptic drugs: insights from a college of american pathologists proficiency testing survey","author":"Krasowski","year":"2021","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"7","key":"10.1016\/j.toxrep.2021.08.005_bib0165","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/bmc.1515","article-title":"A rapid and simple assay for lamotrigine in serum\/plasma by HPLC, and comparison with an immunoassay","volume":"25","author":"Morgan","year":"2011","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.toxrep.2021.08.005_bib0170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.toxrep.2019.12.005","article-title":"Correlation of osmolal gap with measured concentrations of acetone, ethylene glycol, isopropanol, methanol, and propylene glycol in patients at an academic medical center","volume":"7","author":"Greene","year":"2020","journal-title":"Toxicol. Rep."},{"issue":"9","key":"10.1016\/j.toxrep.2021.08.005_bib0175","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3109\/15563650.2014.965828","article-title":"An 11-year review of levetiracetam ingestions in children less than 6 years of age","volume":"52","author":"Lewis","year":"2014","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.toxrep.2021.08.005_bib0180","series-title":"ARK Lamotrigine Assay","year":"2017"},{"issue":"5","key":"10.1016\/j.toxrep.2021.08.005_bib0185","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.ftd.0000245779.64080.30","article-title":"Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry","volume":"28","author":"Beck","year":"2006","journal-title":"Ther. Drug Monit."},{"issue":"8\u20139","key":"10.1016\/j.toxrep.2021.08.005_bib0190","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00228-003-0655-6","article-title":"Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers","volume":"59","author":"Strolin Benedetti","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.toxrep.2021.08.005_bib0195","series-title":"ARK Levetiracetam Assay","year":"2020"},{"issue":"6","key":"10.1016\/j.toxrep.2021.08.005_bib0200","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/2045125316656707","article-title":"Safety profile of lamotrigine in overdose","volume":"6","author":"Alabi","year":"2016","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.toxrep.2021.08.005_bib0205","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1345\/aph.1M617","article-title":"Seizures secondary to lamotrigine toxicity in a two-year-old","volume":"44","author":"Close","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.toxrep.2021.08.005_bib0210","article-title":"Lamotrigine ODT-induced seizure in a 3-year-old child after accidental ingestion","volume":"2019","author":"Griswold","year":"2019","journal-title":"Case Rep. Emerg. Med."},{"issue":"6","key":"10.1016\/j.toxrep.2021.08.005_bib0215","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/17425255.2.6.1009","article-title":"Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy","volume":"2","author":"Biton","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.toxrep.2021.08.005_bib0220","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1059131102001723","article-title":"A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy","volume":"12","author":"Nakken","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.toxrep.2021.08.005_bib0225","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319851652","article-title":"Therapeutic levetiracetam monitoring during pregnancy: \u201cmind the gap\u201d","volume":"10","author":"Berlin","year":"2019","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"6","key":"10.1016\/j.toxrep.2021.08.005_bib0230","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/01.WNL.0000138424.33979.0C","article-title":"Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy","volume":"63","author":"Hirsch","year":"2004","journal-title":"Neurology"},{"issue":"1s","key":"10.1016\/j.toxrep.2021.08.005_bib0235","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.18433\/jpps30081","article-title":"Therapeutic drug monitoring of levetiracetam in select populations","volume":"21","author":"Jarvie","year":"2018","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.toxrep.2021.08.005_bib0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105610","article-title":"Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: recommendations for pregnant women with epilepsy","volume":"169","author":"Wang","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.toxrep.2021.08.005_bib0245","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.seizure.2007.11.027","article-title":"Serum concentration\/dose ratio of levetiracetam before, during and after pregnancy","volume":"17","author":"Westin","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.toxrep.2021.08.005_bib0250","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.seizure.2020.03.009","article-title":"Correlation of levetiracetam concentration in peripheral blood mononuclear cells with clinical efficacy: a sensitive monitoring biomarker in patients with epilepsy","volume":"78","author":"Harby","year":"2020","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.toxrep.2021.08.005_bib0255","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2217\/pgs-2019-0179","article-title":"Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study","volume":"21","author":"Wolking","year":"2020","journal-title":"Pharmacogenomics"}],"container-title":["Toxicology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750021001566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750021001566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:05:51Z","timestamp":1780416351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214750021001566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":51,"alternative-id":["S2214750021001566"],"URL":"https:\/\/doi.org\/10.1016\/j.toxrep.2021.08.005","relation":{},"ISSN":["2214-7500"],"issn-type":[{"value":"2214-7500","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation of elevated lamotrigine and levetiracetam serum\/plasma levels with toxicity: A long-term retrospective review at an academic medical center","name":"articletitle","label":"Article Title"},{"value":"Toxicology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxrep.2021.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}